Probiotic strain from Probi may support metabolic health according to recent study

Photo © AdobeStock.com/Маргарита Медведева

A recent study¹ found that a proprietary strain of Lacticaseibacillus paracasei (from Probi, based in Redmond, WA) may offer users cardiometabilic health benefits. In the study, 130 subjects with metabolic syndrome were randomized to receive either placebo or the probiotic strain daily for 12 weeks. Researchers measured endothelial function by flow-mediated slowing and cardiometabolic health was determined by components and severity of metabolic syndrome.

Results showed that compared to placebo, subjects taking the probiotic strain experienced a greater reduction in remnant cholesterol which is significantly associated with improvements in endothelial function. Additionally, in subjects with ideal compliance of trial protocol, probiotic supplementation lowered triglycerides, alleviated metabolic syndrome severity and delayed weight gain. Researchers observed no obvious effect on insulin sensitivity or pancreatic beta-cell function following supplementation with the probiotic strain.

"The significant impact on metabolic components in subjects with metabolic syndrom, even without dietary restrictions or changes in physical exercise is very promising," said Christina Vegge, director of Discovery & Clinical Research at Probi, in a press release. "The data showed improved endothelial function, lipid profile, blood sugar regulation, reduced bodyweight gain, and prevented elevated BMI compared to the placebo group.”

“Metabolic health is of strategic importance to Probi, and we acknowledge the significant potential of this health area to have a positive impact on numerous lives,” offered Anita Johansen, CEO of Probi. “People are experiencing longer lifespans, but their overall quality of life and health are declining. Our focus is now to explore further how our probiotic can support metabolic health and potentially reduce the risk of cardiovascular disease and in that way enhance peoples´ number of years spent in good health."

Reference

1. Yang, J.; Huang, J.; Huang, Z.; Xu, Y.; Li, W.; Li, W.; Zhu, S.; Zhao, Y.; Ye, B.; Liu, L.; Zhu, J.; Xia, M.; Liu, Y. Cardiometabolic Benefits of Lacticaseibacillus paracasei 8700:2: A Randomized Double-Blind Placebo-Controlled Trial. Clinical Nutrition, 2023, 42(9): P1637-1648. DOI: 10.1016/j.clnu.2023.07.017